“British drug maker AstraZeneca has had promising results from a study trialing its nasal headache spray Zomig in adolescents. The data indicates the drug to be nearly 15% more effective than placebo at reducing headaches one hour after administration.

“Zomig (zolmitriptan) nasal spray 5mg achieved a 58.1% headache response rate in adolescents compared to a 43.3% response in those treated with placebo after one hour, a 14.8% difference.”

Read more at AstraZeneca’s migraine spray proves effective in adolescents

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Monday, June 27th, 2005 at 1:52 pm and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.